These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
67. Pegvisomant therapy in pituitary gigantism: successful treatment in a 12-year-old girl. Rix M; Laurberg P; Hoejberg AS; Brock-Jacobsen B Eur J Endocrinol; 2005 Aug; 153(2):195-201. PubMed ID: 16061823 [TBL] [Abstract][Full Text] [Related]
68. Somatostatin receptors in pituitary function, diagnosis and therapy. Hofland LJ; Lamberts SW Front Horm Res; 2004; 32():235-52. PubMed ID: 15281350 [TBL] [Abstract][Full Text] [Related]
69. The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly. Karavitaki N; Botusan I; Radian S; Coculescu M; Turner HE; Wass JA Clin Endocrinol (Oxf); 2005 Mar; 62(3):282-8. PubMed ID: 15730408 [TBL] [Abstract][Full Text] [Related]
70. Effectiveness of slow-release lanreotide in previously operated and untreated patients with GH-secreting pituitary macroadenoma. Cannavò S; Squadrito S; Curtò L; Almoto B; Trimarchi F Horm Metab Res; 2001 Oct; 33(10):618-24. PubMed ID: 11607883 [TBL] [Abstract][Full Text] [Related]
71. [Treatment of pituitary gland hyperfunction: from acromegaly to prolactinoma]. Schäffler A Internist (Berl); 2006 Dec; 47(12):1215-6, 1218-20, 1222. PubMed ID: 17033781 [TBL] [Abstract][Full Text] [Related]
72. Management of endocrine disease: GH excess: diagnosis and medical therapy. Andersen M Eur J Endocrinol; 2014 Jan; 170(1):R31-41. PubMed ID: 24144967 [TBL] [Abstract][Full Text] [Related]
73. Expression of the growth hormone secretagogue receptor in pituitary adenomas and other neuroendocrine tumors. Korbonits M; Jacobs RA; Aylwin SJ; Burrin JM; Dahia PL; Monson JP; Honegger J; Fahlbush R; Trainer PJ; Chew SL; Besser GM; Grossman AB J Clin Endocrinol Metab; 1998 Oct; 83(10):3624-30. PubMed ID: 9768675 [TBL] [Abstract][Full Text] [Related]
74. Hormone secretion by pituitary adenomas is characterized by increased disorderliness and spikiness but more regular pulsing. Roelfsema F; Pereira AM; Biermasz NR; Veldhuis JD J Clin Endocrinol Metab; 2014 Oct; 99(10):3836-44. PubMed ID: 25014002 [TBL] [Abstract][Full Text] [Related]
75. Dopamine D2 receptor imaging in pituitary adenomas using iodine-123-epidepride and SPECT. Pirker W; Riedl M; Luger A; Czech T; Rössler K; Asenbaum S; Angelberger P; Kornhuber J; Deecke L; Podreka I; Brücke T J Nucl Med; 1996 Dec; 37(12):1931-7. PubMed ID: 8970508 [TBL] [Abstract][Full Text] [Related]
76. Medical therapy of pituitary adenomas: effects on tumor shrinkage. Colao A; Pivonello R; Di Somma C; Savastano S; Grasso LF; Lombardi G Rev Endocr Metab Disord; 2009 Jun; 10(2):111-23. PubMed ID: 18791829 [TBL] [Abstract][Full Text] [Related]
77. The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly. Colao A; Auriemma RS; Pivonello R Pituitary; 2016 Apr; 19(2):210-21. PubMed ID: 26290466 [TBL] [Abstract][Full Text] [Related]
78. Disappearance of a growth hormone secreting macro adenoma during long-term somatostatin analogue administration and recurrence following somatostatin withdrawal. Livadas S; Hadjidakis DJ; Argyropoulou MI; Stamatelatou M; Kelekis D; Raptis SA Hormones (Athens); 2006; 5(1):57-63. PubMed ID: 16728386 [TBL] [Abstract][Full Text] [Related]
79. Management of pituitary tumors. Shimon I; Melmed S Ann Intern Med; 1998 Sep; 129(6):472-83. PubMed ID: 9735086 [TBL] [Abstract][Full Text] [Related]
80. Characterization of the ability of a, second-generation SST-DA chimeric molecule, TBR-065, to suppress GH secretion from human GH-secreting adenoma cells. Cuny T; Graillon T; Defilles C; Datta R; Zhang S; Figarella-Branger D; Dufour H; Mougel G; Brue T; Landsman T; Halem HA; Culler MD; Barlier A; Saveanu A Pituitary; 2021 Jun; 24(3):351-358. PubMed ID: 33433890 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]